AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N

Links:

TYK2 Inhibitor Promising for Moderate-to-Severe Psoriasis in Phase 3 Studies https://www.medscape.com/viewarticle/tyk2-inhibitor-promising-moderate-severe-p…
Dr. John Cush
RheumNow
Apr-02-2026
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×